Darren Foard - Concepedia

Author

Darren Foard

University College London

Also Known As

D Foard, D. Foard, Darren Foard, Foard, D, Foard, DM

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University College London The Royal Free Hospital University of Pavia Heidelberg University National and Kapodistrian University of Athens

About

Darren Foard is an author at University College London specializing in alzheimer's disease, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	187
2	Pharmacology	2	2	150
3	Health Sciences	1	1	53
4	Nephrology	1	1	37
5	Pathology	1	1	37

Darren Foard

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Ashutosh Wechalekar, Stefan Schönland, Efstathios Kastritis, Blood	2013	505
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Christopher P. Venner, Thirusha Lane, Darren Foard, Blood	2012	276
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib Richa Manwani, Oliver Cohen, Faye Sharpley, Blood	2019	185
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis Oliver Cohen, Andreia Ismael, Babita Pawarova, European Heart Journal	2021	104
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis Christopher P. Venner, Julian D. Gillmore, Sajitha Sachchithanantham, Leukemia Alzheimer's DiseaseAl AmyloidosisPharmacologyMatched ComparisonRisk-adapted Cyclophosphamide	2014	97
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis Eli Muchtar, Angela Dispenzieri, Brendan Wisniowski, Journal of Clinical Oncology	2022	71
Lenalidomide and dexamethasone for systemic <scp>AL</scp> amyloidosis following prior treatment with thalidomide or bortezomib regimens Shameem Mahmood, Christopher P. Venner, Sajitha Sachchithanantham, British Journal of Haematology Bortezomib RegimensAmyloid DepositsAlzheimer's DiseaseAl AmyloidosisPharmacology	2014	53
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor Tamer Rezk, Helen J. Lachmann, Marianna Fontana, Kidney International UrologyAlzheimer's DiseaseRenal FunctionKidney ResearchMedicine	2017	37
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Blood	2018	31
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib Sriram Ravichandran, Oliver Cohen, Steven Law, Blood Cancer Journal	2021	31

Page 1